Dokumente
Suchschritt : FT=glucosamine AND FT=osteoarthritis
» Fenster schließen »

2/189 von 416 DIMDI: MEDLINE (ME60) © NLM

ND: | ME12860582
PMID: | 12860582
LR: | 20061115
CED: | 20030715
DCO: | 20030805
Autoren: | Scroggie DA; Albright A; Harris MD
Titel: | The effect of glucosamine-chondroitin supplementation on glycosylated hemoglobin levels in patients with type 2 diabetes mellitus: a placebo-controlled, double-blinded, randomized clinical trial.
Quelle: | Archives of internal medicine; VOL: 163 (13); p. 1587-90 /20030714/
PM: | Print
SU: | AIM IM
Sprache: | English
CY: | United States
JID: | 0372440
ISSN: | 0003-9926
CO: | AIMDAP
Institution: | Department of Rheumatology, 59th Medical Wing, Wilford Hall Medical Center, Lackland Air Force Base, Lackland, TX 78236, USA. Daren.Scrogie@lackland.af.mil
DT: | Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, Non-P.H.S.
Schlagwörter
CT: | AGED; ANALYSIS OF VARIANCE; BLOOD GLUCOSE/*drug effects; CHONDROITIN/*administration & dosage; DIABETES MELLITUS, TYPE 2/*complications; DIETARY SUPPLEMENTS/*; DOUBLE-BLIND METHOD; FEMALE; GLUCOSAMINE/*administration & dosage; HEMOGLOBIN A, GLYCOSYLATED/*drug effects; HUMANS; MALE; OSTEOARTHRITIS/complications; OSTEOARTHRITIS/*drug therapy; STATISTICS, NONPARAMETRIC
CTG: | ALTE MENSCHEN; VARIANZANALYSE; BLUTGLUCOSE/*Arzneimittelwirkungen; CHONDROITIN/*Verabreichung & Dosierung; DIABETES MELLITUS, NICHTINSULINPFLICHTIGER/*Komplikationen; NAHRUNGSERGÄNZUNGSMITTEL/*; DOPPELBLINDMETHODE; WEIBLICH; GLUCOSAMIN/*Verabreichung & Dosierung; HÄMOGLOBIN A, GLYCOSYLIERTES/*Arzneimittelwirkungen; MENSCH; MÄNNLICH; OSTEOARTHROSE/Komplikationen; OSTEOARTHROSE/*Arzneimitteltherapie; STATISTIK, NICHTPARAMETRISCHE
TE: | Blood Glucose; Hemoglobin A, Glycosylated; Glucosamine/3416-24-8; Chondroitin/9007-27-6
CR: | 3416-24-8; 9007-27-6
NOTE: | Comment in: Arch Intern Med. 2004 Apr 12;164(7):807; Ref.PMID: 15078657
AB: | BACKGROUND: With increasing use of glucosamine-containing supplements for the treatment of osteoarthritis, there is increasing concern in the medical community about possible toxic effects. The present study was undertaken to determine whether glucosamine supplementation altered hemoglobin A1c concentrations in patients with well-controlled diabetes mellitus. OBJECTIVE: To evaluate possible effects of glucosamine supplementation on glycemic control in a selected population of patients with type 2 diabetes mellitus. DESIGN: Placebo-controlled, double-blinded, randomized clinical trial. SETTING: Outpatient, diabetes monitoring clinic. PATIENTS: Patients were typically elderly patients, evenly divided between men and women. Most of the patients were being treated with 1 or 2 drugs for glycemic control. INTERVENTION: In daily doses for 90 days, patients received either placebo or a combination of 1500 mg of glucosamine hydrochloride with 1200 mg of chondroitin sulfate (Cosamin DS; Nutramax Laboratories Inc, Edgewood, Md).Main Outcome Measure Hemoglobin A1c levels before and after 90 days of therapy. RESULTS: There were 4 withdrawals from the glucosamine-treated group. Three were related to comorbidities (myocardial infarction, congestive heart failure, and atrial fibrillation) and 1 to a possible adverse reaction (excessive flatus). No other patient reported any adverse effects of glucosamine therapy, and no patient had any change in their diabetes management. Mean hemoglobin A1c concentrations were not significantly different between groups prior to glucosamine therapy. Posttreatment hemoglobin A1c concentrations were not significantly different between groups, nor were there any significant differences within groups before and after treatment. CONCLUSION: This study demonstrates that oral glucosamine supplementation does not result in clinically significant alterations in glucose metabolism in patients with type 2 diabetes mellitus.

» Volltext »
» Fenster schließen »